Biomarkers are potentially a non-invasive and universal diagnostic tool that focuses on molecular markers over the phenotypic differences described through biopsy. GBM microvesicles may prove to be useful in this respect. Microvesicles are plasma membrane-derived membrane-enclosed particles that are released from cells through membrane fission and can carry mRNA, miRNA, and proteins from the parent cell. When these microvesicles are GBM derived, the tumor-specific contents can adjust the nearby microenvironment to be more hospitable to tumor growth. Patient serum may provide prognostic information as it has also been used to detect a small non-coding RNA, RNU6-1, which is an independent predictor of GBM. Clearly, the serum composition of GBM patients should be further studied as it may non-invasively provide highly valuable prognostic information for treating GBM beyond the current paradigms.
Glioblastoma multiforme laboratory tests
Oligoastrocytoma laboratory tests
Oligodendroglioma laboratory tests
Glioma physical examination
Glioblastoma multiforme physical examination
Meningioma physical examination
Coma MRI
Ganglioglioma physical examination